Analysts think SLS stock price could increase by 324%
Jun 14, 2024, 6:29 AM
-21.80%
What does SLS do
SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company based in New York City, focuses on developing immunotherapeutics for cancer, including GPS and GFH009, targeting various cancer types. Formed in 2008, SELLAS licenses key products like GPS from Memorial Sloan Kettering and GFH009 from GenFleet Therapeutics, aiming at broad cancer indications.
4 analysts think SLS stock price will increase by 323.53%. The current median analyst target is $6.12 compared to a current stock price of $1.45. The lowest analysts target is $4.04 and the highest analyst target is $7.88.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.